Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Depreciation & Amortization (IS)Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ocular Therapeutix (OCUL) Long-Term Debt Issuances (2017 - 2019)

Ocular Therapeutix has reported Long-Term Debt Issuances over the past 2 years, most recently at -$70000.0 for Q2 2019.

For Q2 2019, Long-Term Debt Issuances changed N/A year-over-year to -$70000.0; the TTM value through Sep 2021 reached -$70000.0, changed N/A, while the annual FY2023 figure was $82.5 million, N/A changed from the prior year.
Long-Term Debt Issuances for Q2 2019 was -$70000.0 at Ocular Therapeutix, down from $37.3 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $37.3 million in Q1 2019 and troughed at -$70000.0 in Q2 2019.